Skip to content

    Astrazeneca Phar

    ASTRAZENGood
    Healthcare·8 Aug 2024
    Management Summary

    AstraZeneca India is undergoing a significant strategic transition from a manufacturing-led model to a specialist biopharmaceutical trading organization. The company delivered robust double-digit growth in FY24 and started Q1 FY25 with strong underlying momentum despite the loss of exclusivity for key brands. Management is focused on accelerating the launch of the global innovative pipeline in India to support the parent company's $80 billion revenue target by 2030.

    Highlights

    7

    • Total Revenue for FY23-24 reached ₹1,330 crores, representing a 29% YoY growth.

    • Q1 FY25 revenue growth (excluding Lynparza) stood at 45% YoY and 8% on a sequential basis.

    • Profit Before Tax (PBT) grew by 64% in FY24, with EPS increasing 63% to ₹64.60.

    • Oncology segment remains the largest contributor, with Tagrisso alone accounting for 26.53% of total sales.

    • An exceptional charge of ₹57 crores was recorded in Q1 FY25 related to the closure of the Bangalore manufacturing plant.

    • The company declared a dividend of ₹24 per share for the financial year 2023-24.

    • Inventory holding improved to 64 days in FY24 compared to 74 days in the previous year.

    What Changed1

    vs Q1 FY26

    Risks discussed4 → 3 (-1)
    Key financials

    Metrics

    6

    Periods

    3

    Headline

    4
    • EPS
      ₹64.6
      YoY+63%
    • Material Consumption to Sales
      45.9%
    • Employee Costs as % of Sales
      18.6%
    • Book Value Per Share
      ₹284.77

    Q1 FY25

    1
    • Exceptional Charge
      ₹57 Cr

    FY24

    1
    • Revenue
      ₹1,330 Cr
      YoY+29.0%

    Segment breakdown

    Oncology
    ₹319.9 Cr Tagrisso Sales₹200.7 Cr Imfinzi Sales₹131.3 Cr Lynparza Sales42% Growth Rate
    Biopharmaceutical (CVRM & Respiratory)
    ₹181.1 Cr Brilinta Sales₹75.2 Cr Forxiga Sales27% Brilinta Growth
    List

    Guidance & targets

    2
    CategoryTargetPriority
    Other
    Plant Sale Realization
    Completion of sale
    		Medium
    Revenue
    India Revenue Growth
    30%
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Gross Margin Compression

    Margins have been declining over the last two quarters due to product mix shifts and the transition to a trading model. — Analyst acknowledged

    medium

    Loss of Exclusivity (LOE)

    Key brands like Forxiga and Brilinta have faced or are facing loss of exclusivity, requiring new launches to offset revenue pressure. — Management acknowledged

    medium

    Plant Exit Costs

    The closure of the Bangalore site involves one-time exceptional charges (₹57 cr) and potential employee-related liabilities. — Both acknowledged

    low

    Areas of Evasion(2)

    • Breakdown of the ₹57 crore exceptional charge
    • Specific realization value expected from the Bangalore land sale

    Q&A highlights

    3

    “All these changes in the gross margin material cost can happen because of the mixed changes and the fact that we are becoming a specialist organization which is more focusing on the trading products.”

    Explains the structural shift in profitability as the company moves away from in-house manufacturing to importing/trading global products.

    asked by Harsh Bhatia

    2 min read5 chapters

    Detailed Narrative

    01

    Oncology Portfolio Drives Growth

    The Oncology business is the primary engine for AstraZeneca India, growing at 42% YoY, significantly faster than the market. Tagrisso remains the flagship brand, contributing ₹319.9 million (26.53% of total sales), while Imfinzi and Lynparza also showed robust performance. The recent launch of Enhertu in January 2024 for HER-2 positive metastatic breast cancer is expected to be a key catalyst for future growth in the segment.

    02

    Strategic Exit from Manufacturing

    AstraZeneca is exiting its Bangalore manufacturing site as part of a global strategic review. This transition resulted in a ₹57 crore exceptional charge📎 in Q1 FY25, covering employee-related aspects and other closure costs. The company intends to sell the site, which is described as a 'prime property' near the airport, with realizations expected over the next 12-15 months. This move shifts the company toward a 100% trading model for innovative global products.

    03

    Biopharmaceutical Resilience Amid LOE

    Despite the loss of exclusivity (LOE) for Brilinta and Forxiga, the Biopharmaceutical division grew by 8%. Brilinta achieved 27% growth YoY by sustaining market leadership in the OAP market. The company is also expanding its respiratory portfolio through an exclusive distribution agreement with Mankind Pharma for Symbicort, aiming to improve access across India.

    04

    Rare Disease Market Entry

    AstraZeneca officially entered the Indian Rare Disease market with the launch of Koselugo for pediatric patients with neurofibromatosis type 1 (NF1). Management highlighted that finding and diagnosing rare disease patients is a key challenge, and they are leveraging digital tools and partnerships with advocacy groups like ORDI to build awareness and widen the national policy ambit for rare diseases.

    05

    Digital and AI Integration

    The company is heavily investing in digital transformation, reaching over 5,000 'white space' healthcare professionals through digital channels. Initiatives include the 'Lung Mitra' platform and AI-based screening collaborations with the governments of Goa and Karnataka for early lung cancer detection. Internally, the company has launched 'easy chat GPT' for employees to simplify operations and accelerate innovation delivery.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.